You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHS
Project SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viabilitySTTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: NANOHYBRIDS INC Topic: N
ABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: COLUMBUS NANOWORKS, INC. Topic: 400
Fluorescent nanodiamonds are biocompatibleinfinitely photostableand fluoresce in a variety of wavelengthsincluding the near infraredNIRregionThese characteristics suggest transformative applications in areas ranging from pure biological research to biomedical imagingwhere protein conjugated nanodiamonds could be targeted to specific tissues in living patients or even structures within individual c ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Lacerta Therapeutics, Inc. Topic: 102
Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancerSBC: 7 Hills Pharma LLC Topic: 102
Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: IMMUNOBLUE, LLC Topic: NCI
PROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: BRILLIANT BIOSCIENCES INC. Topic: NIA
One in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Universal Adherence LLC Topic: N
Project Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's DiseaseSBC: Amprion, Inc. Topic: NIA
ABSTRACT This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluidswhich could be used for the biochemical diagnosis of Alzheimerandapos s diseaseADand related tauopathiesAD is the most common dementia in the elderly population and one of the leading causes of death in the develop ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Truvitech, LLC Topic: NCATS
PROJECT SUMMARY Drugs act by altering the activities of particular componentstargetswithin a cell or organismThusdrug discovery campaigns begin by identifying a targetfollowed by screening this target with compounds to identify leads that can be developed into a drugUnfortunatelyidentifying effective drug targets for a given diseaselet alone for individual patientse gin highly heterogeneous cancer ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health